Eliem Therapeutics announced the appointments of Brett Kaplan, M.D., as Chief Operating Officer, COO, and Nishi Rampal, M.D., as Senior Vice President, SVP, Clinical Development. Before joining Eliem, Dr. Kaplan served as President, Chief Financial and Corporate Development Officer at Chroma Medicine. Prior to Eliem, Dr. Rampal was the Executive Director Clinical Development at Horizon Therapeutics.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELYM:
- Eliem Therapeutics Announces Additions to its Leadership Team
- Eliem Therapeutics Reports Second Quarter Financial Results
- Eliem Therapeutics files to sell 36.8M shares of common stock for holders
- RA Capital raises Eliem Therapeutics position by 13M shares or $50M
- Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes